

# Make better pipeline decisions with Agentic AI

Drive insight generation from day one, empowering teams, de-risking pipeline decisions, and delivering impact with top-quality multimodal data and cutting-edge agentic AI.

## Challenges


- Scattered and fragmented data hinders fast and confident decisions
- Stakeholders can't query or stress-test data easily
- Data access requires coding and external tools
- Outsourced intelligence limits flexibility
- Generalist LLMs not fit-for-purpose for scientific tasks

## PRO is the answer

- Unifies data into one decision-making tool, linking biology to clinical impact
- Natural-language queries unlock complex data instantly
- Empowers non-coders with intuitive data interaction
- Custom AI accelerates discovery using internal and external data
- Interoperable agents for biological tasks accessible via major platforms



We've packaged nine years of cutting edge AI and multimodal patient data into an agentic AI software for pharma:




Owkin's high quality multimodal patient data (including spatial)

+



Your data (shared safely and securely with full IP protections)

+



9 years of AI tools  
Interoperable agents to find and describe the what and why of biology



- Pharma decision-making tool
- Grounded in multimodal patient data
- Connects deep biology to clinical impact



Do we observe differences in response rate to immune checkpoint inhibitors in high vs low lymphocyte density in tumor for NSCLC MOSAIC patients?

Do we observe differences in response rate to immune checkpoint inhibitors in high vs low lymphocyte density in tumor for NSCLC MOSAIC patients?

Thought process

Summary

Survival Analysis By Lymphocyte Density For NSCLC Patients Receiving Immunotherapy


Based on the analysis of NSCLC patients from the MOSAIC dataset who received immune checkpoint inhibitors (ICIs), there appears to be a difference in response rate between high and low lymphocyte density groups.

Ask follow up

Survival Analysis By Lymphocyte Density For NSCLC Patients Receiving Immunotherapy

Survival Analysis by Lymphocyte Density for NSCLC Patients Receiving Immunotherapy

Analysis by Lymphocyte Density for NSCLC Patients Receiving Immunotherapy



JB

K Pro beta — accuracy not guaranteed. Verify key info.

# PRO Agents and Tools

## Your AI-Powered Drug Discovery & Development Suite

K Pro consists of biological reasoning agents made interoperable for easy access via major platforms, designed for your goals.



### THE FOUNDATION

## Data Transformation Agents

From raw data to insights in hours, not weeks.

### Key capabilities:

- Automate discovery, standardization, and transformation of biomedical data
- Reduce data onboarding from weeks to hours
- Transform multimodal data to analysis-ready: clinical/tabular, RNA-seq, single-cell, and more
- Augment data using AI, to transform it into quantified biology




## Due Diligence Agents

Evaluate opportunities with confidence.

### Key capabilities:

- Assess drug/program opportunities early in development
- Compare assets against clinical trial benchmarks
- Evaluate antibody developability and small molecule binding
- Generate standardized diligence packs covering mechanism, IP, safety, and competitive positioning



## Patient & Population Agents

Define the right patients before you start a trial.

### Key capabilities:

- Identify responder signatures and successful therapy patterns
- Converse with histological data to understand the tumor microenvironment, characterize patient populations, and derive actionable biomarkers
- Navigate biological features across multimodal data
- Define optimal populations maximizing drug response likelihood

### CASE STUDY



### HistoPlus

Automatically detect cell types and tissue structures from histology data.



## Clinical Trial Agents

Enrich early trial data with real-world insights.

### Key capabilities:

- Interrogate trial data for efficacy, biomarker associations, and population insights
- Match trial populations to real-world data for contextualization
- Identify biomarkers and inclusion/exclusion criteria for next phases

# PRO is fuelled by the highest quality multimodal patient data

Access to 19 expertly curated and integrated public datasets and 25M articles

- Instant access to harmonized, analysis-ready data.
- We spent 2000 man days curating this data so you don't have to.
- Agents specifically trained to provide clear, coherent responses from specific literature.
- Data is augmented using AI, to transform it into quantified biology.

Access to the spatial and single cell omics dataset, MOSAIC and Owkin Patient Data Network

- Clean, AI-ready spatial data for 2,200+ patients
- Six modalities per patient for robust, multi-dimensional insights
- Highly representative cohorts for high-unmet-need indications
- Structured for rapid, intelligent analysis

## Deep dive into Owkin's distributed multimodal patient data network

50

Petabytes of data

4 therapy areas

Onco, I&I, CVD, Neuro

141

World-leading KOLs

14 countries

Countries in EU and USA

50%

of the 20 top academic hospitals worldwide

840 hospitals

100 tier 1 leading academic institutions and path labs

## K Pro's data catalogue grows as our network expands and new consortia data is generated

Available

In progress

Mapped

 HOPE

HAEMATOLOGY & ONCOLOGY PARTNER NETWORK



mosaic

MOSAIC is our deep multimodal and spatial oncology dataset. It includes 6 modalities for 2,600+ patients across 11 cancer indications.

 MIIDAS

MULTIMODAL IMMUNOLOGY & INFLAMMATION DATA ATLAS

The first spatial atlas of multimodal data in immunology and inflammation to support optimal patient stratification and enable treatment discovery.

 CORE

CARDIO & METABOLIC OUTCOMES RESEARCH NETWORK

Patient data across the cardiovascular-kidney-metabolic syndrome spectrum, from early metabolic risk factors through advanced clinical disease stages.

 MINDS

MULTIMODAL INTEGRATION OF ALZHEIMERS NEUROLOGY DATASETS

Comprehensive mapping of CNS data availability from partner centers with a focus on Alzheimer's.

For data licensing enquiries outside of K Pro - including direct data transfer - please contact the Owkin team at [owkin.com/contact](https://owkin.com/contact)

# Why use Owkin's agentic AI?

Decisions driven by multimodal, clinically grounded data and enhanced by cutting edge AI tools

## 1 Convenience and speed

All in one place.  
Interoperable for easy access via major platforms.  
Accessible via AWS Marketplace as a SaaS platform.

## 2 Clinical accuracy

K Pro pulls from the right data, multimodal + clinical outcomes data.

## 3 Boosts collaboration

Used across teams.  
Eliminate data silos between teams.

## 4 Reach market faster

Simulating biology to speed up scientific iteration.  
Accelerate critical decisions with rapid insights from multimodal data.

Higher confidence in decisions

Decreasing time to value

Moving faster than competitors

# Why work with Owkin?



## Deep AI experience

Nine years developing cutting-edge AI, and 81 published research papers.




## Trusted by top biopharmas

Partner with eight out of top ten pharma.



## Extensive patient data network

840 hospitals from 100 academic institutions.



## Platform interoperability

Agents and tools that work where you work. Compatible with major AI and SaaS platforms.



## Used by researchers from top institutions

K Pro FREE 1000+ users.



## Compliance

ISO 27001 (Information security)  
ISO 13485 (Medical device quality)  
AWS-hosted: Scalable and secure.



Contact us today to set up your free demo

Visit [www.owkin.com/connect/book-a-demo](https://www.owkin.com/connect/book-a-demo)  
or email our team at [sales@owkin.com](mailto:sales@owkin.com)



Get in touch with us at [owkin.com/contact](https://owkin.com/contact)

© 2025 Owkin, Inc | Public information | Ref. 059V3

 **OWKIN.COM**